摘要
背景:尽管已知阿尔茨海默病(AD)与人脑中淀粉样β肽(Aβ)的进行性累积有关,但其致病作用必须完全澄清。 Aβ从血脑屏障移动到血浆,并且脑中Aβ产生增加可能与血液中更高的Aβ浓度有关。最近的一项研究评估了人类红细胞(RBCs)中的Aβ40和Aβ42水平,证实了RBC中Aβ浓度随年龄增长而增加。 目的:本研究的目的是调查红斑相关Aβ(iAβ)水平在受痴呆影响的受试者中是否与对照组以及根据患者的认知障碍或不同的痴呆亚型有所不同。 方法:为了回答这些问题,我们评估了116名患者中的iAβ40和iAβ42水平:32名健康对照,39名诊断为血管性痴呆(VaD),14名轻度认知障碍(MCI)和31名AD。 结果:在这个人群中,我们发现对照组和对照组患者之间iAβ42的差异显着。此外,iAβ42在痴呆与MCI之间显着不同。与VaD相比,AD也显示出不同的iAβ42水平。相反,iAβ40没有发现差异。所有分析均针对潜在的混杂因素进行调整,如年龄,性别和血红蛋白浓度。还发现使用MMSE评分作为连续变量增加iAβ42浓度与认知衰退进展之间的直接相关性。 结论:我们的研究结果支持iAβ42可能是早期识别痴呆和预测认知障碍的工具。
关键词: 阿尔茨海默病,认知障碍,淀粉样蛋白β肽,生物标志物,红细胞相关Aβ42,Aβ40
Current Alzheimer Research
Title:Erythrocyte Associated Amyloid-β as Potential Biomarker to Diagnose Dementia
Volume: 15 Issue: 4
关键词: 阿尔茨海默病,认知障碍,淀粉样蛋白β肽,生物标志物,红细胞相关Aβ42,Aβ40
摘要: Background: Although it is known that Alzheimer's disease (AD) is associated with the progressive accumulation of amyloid β-peptide (Aβ) in the human brain, its pathogenic role has to be completely clarified. Aβ moves from the bloodbrain barrier to the plasma and an increased Aβ production in brain could be associated with higher Aβ concentrations in blood. A recent study has evaluated Aβ40 and Aβ42 levels in human red blood cells (RBCs) with evidence of agedependent higher Aβ concentration in RBCs.
Objective: The aim of the study was to investigate if erythrocyte associated Aβ (iAβ) levels could be different in subjects affected by dementia in comparison with controls and according to the patient’s cognitive impairment or different dementia subtypes.
Method: To answer these questions we assessed iAβ40 and iAβ42 levels in 116 patients: 32 healthy controls, 39 with diagnosis of vascular dementia (VaD), 14 mild cognitive impairment (MCI) and 31 AD.
Results: In this population we found significant differences in iAβ42 between controls and cognitive impaired patients. Moreover, iAβ42 significantly differed between dementia vs MCI. AD also showed different iAβ42 levels as compared to VaD. Conversely, no differences were found for iAβ40. All the analyses were adjusted for potential confounders like age, gender and Hb concentration. A direct correlation between increasing iAβ42 concentration and the progression of the cognitive decline using the MMSE score as continuous variable was also found.
Conclusion: Our findings support the evidence that iAβ42 could be an instrument to early recognize dementia and predict cognitive impairment.
Export Options
About this article
Cite this article as:
Erythrocyte Associated Amyloid-β as Potential Biomarker to Diagnose Dementia, Current Alzheimer Research 2018; 15 (4) . https://dx.doi.org/10.2174/1567205014666171110160556
DOI https://dx.doi.org/10.2174/1567205014666171110160556 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neuropsychiatric and Cognitive Symptoms in Spinocerebellar Ataxia: Relationship to Neuropathological Differences
Current Psychiatry Reviews Development of Subjective Cognitive Decline
Neuroscience and Biomedical Engineering (Discontinued) Induction of Molecular Chaperones as a Therapeutic Strategy for the Polyglutamine Diseases
Current Pharmaceutical Biotechnology Recent Progress in Pharmacological and Non-Pharmacological Treatment Options of Major Depression
Current Pharmaceutical Design Pharmacological Intervention at Ionotropic Glutamate Receptor Complexes
Current Pharmaceutical Design Neurocysticercosis: The Enigmatic Disease
Central Nervous System Agents in Medicinal Chemistry Differential Cued-Stroop Performance in Cognitively Asymptomatic Older Adults with Biomarker-Identified Risk for Alzheimer’s Disease: A Pilot Study
Current Alzheimer Research Alpha<sub>1</sub>-Adrenergic Receptor Antagonists Use in Treatment and Prevention of Psychiatric Disorders: A Review
Current Psychopharmacology Polyphenols as Potential Inhibitors of Amyloid Aggregation and Toxicity:Possible Significance to Alzheimers Disease
Mini-Reviews in Medicinal Chemistry Immunotherapy for Alzheimers Disease: Rational Basis in Ongoing Clinical Trials
Current Pharmaceutical Design Interventions to Reduce Cardiovascular Risk in Children with Type 1 Diabetes
Current Diabetes Reviews Endothelial Dysfunction and Atherosclerosis: Focus on Novel Therapeutic Approaches
Recent Patents on Cardiovascular Drug Discovery Detection of Mild Cognitive Impairment Based on Virtual Reality: A Scoping Review
Current Alzheimer Research Modulatory Activity of Soluble Beta Amyloid on HPA Axis Function in Rats
Current Pharmaceutical Design Therapeutic Advancement in Alzheimer Disease: New Hopes on the Horizon?
CNS & Neurological Disorders - Drug Targets Inhibitors of the 5-Lipoxygenase Pathway in Atherosclerosis
Current Pharmaceutical Design Pharmacology and Therapeutics of Gabapentin in the Treatment of Psychiatric Disorders; Present and Future Perspectives
Current Neuropharmacology Targeting Generation of Antibodies Specific to Conformational Epitopes of Amyloid β-Derived Neurotoxins
CNS & Neurological Disorders - Drug Targets The Anticholinesterase Activity of Three Local Food Spices and Their Anti-Alzheimer Application
Current Nutraceuticals Nattokinase: An Updated Critical Review on Challenges and Perspectives
Cardiovascular & Hematological Agents in Medicinal Chemistry